At the recent European Association of Nuclear Medicine meeting in Barcelona, researchers from the British Columbia Cancer Research Institute and the University of British Columbia reported the development and preclinical evaluation of bispecific radiotracers designed to target prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP).